These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8570260)

  • 1. [Degeneration of catecholaminergic neurons].
    Chatellard-Causse C; Feuerstein C
    Pathol Biol (Paris); 1995 Sep; 43(7):577-80. PubMed ID: 8570260
    [No Abstract]   [Full Text] [Related]  

  • 2. [Mechanism of cell death in neurodegenerative disorders: apropos of Parkinson disease].
    Agid Y
    C R Seances Soc Biol Fil; 1993; 187(1):37-46. PubMed ID: 8242421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Free radicals and ailing proteins--the culprits behind Parkinson disease?].
    Smith R; Lotharius J; Brundin P
    Lakartidningen; 2003 Apr; 100(15):1324-6, 1329-30. PubMed ID: 12739402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are dopaminergic neurons selectively vulnerable to Parkinson's disease?
    Agid Y; Ruberg M; Javoy-Agid F; Hirsch E; Raisman-Vozari R; Vyas S; Faucheux B; Michel P; Kastner A; Blanchard V
    Adv Neurol; 1993; 60():148-64. PubMed ID: 8420132
    [No Abstract]   [Full Text] [Related]  

  • 5. Oxidative stress to dopaminergic neurons as models of Parkinson's disease.
    Gille G; Hung ST; Reichmann H; Rausch WD
    Ann N Y Acad Sci; 2004 Jun; 1018():533-40. PubMed ID: 15240412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of dopamine biosynthesis by tetrahydropapaveroline.
    Kim YM; Kim MN; Lee JJ; Lee MK
    Neurosci Lett; 2005 Sep; 386(1):1-4. PubMed ID: 16026929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Iron homeostasis and Parkinson's disease].
    Faucheux BA; Hirsch EC
    Ann Biol Clin (Paris); 1998 Jul; 56 Spec No():23-30. PubMed ID: 9827211
    [No Abstract]   [Full Text] [Related]  

  • 8. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.
    Maingay M; Romero-Ramos M; Carta M; Kirik D
    Neurobiol Dis; 2006 Sep; 23(3):522-32. PubMed ID: 16806952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra.
    Chu Y; Kompoliti K; Cochran EJ; Mufson EJ; Kordower JH
    J Comp Neurol; 2002 Aug; 450(3):203-14. PubMed ID: 12209851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Degeneration of dopaminergic neurons in the substantia nigra of zitter mutant rat and protection by chronic intake of Vitamin E.
    Ueda S; Sakakibara S; Nakadate K; Noda T; Shinoda M; Joyce JN
    Neurosci Lett; 2005 Jun; 380(3):252-6. PubMed ID: 15862896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aging, disease and death of nerve cells.
    Agid Y; Hirsch E; Anglade P; Michel P; Brugg B; Ruberg M
    Acta Neurol Belg; 1996 Sep; 96(3):219-23. PubMed ID: 8886107
    [No Abstract]   [Full Text] [Related]  

  • 12. Relationship among alpha-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia nigra.
    Mori F; Nishie M; Kakita A; Yoshimoto M; Takahashi H; Wakabayashi K
    J Neuropathol Exp Neurol; 2006 Aug; 65(8):808-15. PubMed ID: 16896314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine and Parkinson's disease: is the killer in the house?
    Chesselet MF
    Mol Psychiatry; 2003 Apr; 8(4):369-70. PubMed ID: 12740592
    [No Abstract]   [Full Text] [Related]  

  • 14. Pesticides and metals induced Parkinson's disease: involvement of free radicals and oxidative stress.
    Singh C; Ahmad I; Kumar A
    Cell Mol Biol (Noisy-le-grand); 2007 May; 53(5):19-28. PubMed ID: 17543230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
    Chu Y; Kordower JH
    Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The progression of Parkinson disease: a hypothesis.
    Lang AE
    Neurology; 2007 Mar; 68(12):948-52. PubMed ID: 17372132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The molecular mechanisms of dopamine toxicity.
    Barzilai A; Daily D; Zilkha-Falb R; Ziv I; Offen D; Melamed E; Shirvan A
    Adv Neurol; 2003; 91():73-82. PubMed ID: 12442665
    [No Abstract]   [Full Text] [Related]  

  • 18. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism.
    Muñoz A; Rey P; Guerra MJ; Mendez-Alvarez E; Soto-Otero R; Labandeira-Garcia JL
    Neuropharmacology; 2006 Jul; 51(1):112-20. PubMed ID: 16678218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson's disease.
    Ahlskog JE
    Mov Disord; 2005 Mar; 20(3):271-82. PubMed ID: 15580550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease.
    Xu J; Kao SY; Lee FJ; Song W; Jin LW; Yankner BA
    Nat Med; 2002 Jun; 8(6):600-6. PubMed ID: 12042811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.